Analyse NeurAxis, Inc. (NRXS) — Kairos Score 71/100

À propos de NeurAxis, Inc.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Informations clés

🕴️ Activité des initiés (90 jours)

6 transactions — 3 achats et 0 ventes déclarés par les dirigeants de NeurAxis, Inc..

🏦 Hedge Funds

14 fonds institutionnels déclarent une position sur NRXS dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur NRXS.

• NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
• NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.